Lakefront Biotherapeutics (LKFT) EBITDA (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has 13 years of EBITDA data on file, last reported at -$74.6 million in Q1 2026.

• EBITDA for Q1 2026 came in at -$74.6 million, up 55.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $446.3 million (up 329.45% YoY), and the FY2025 annual result was $343.4 million, up 270.65% from the prior year.
• EBITDA fell to -$74.6 million in Q1 2026 per LKFT's latest filing, from $881.4 million in the prior quarter.
• Over five years, EBITDA peaked at $881.4 million in Q4 2025 and troughed at -$538.5 million in Q3 2025.
• A 5-year average of $21.7 million and a median of -$15.4 million in 2023 frame the typical range for EBITDA.
• The sharpest annual moves came in 2023 and 2024: EBITDA jumped 5629.05% in 2023, then slumped 1276.11% in 2024.
• A 5-year view of EBITDA shows it stood at $4.1 million in 2022, then jumped by 5629.05% to $233.8 million in 2023, then sank by 67.41% to $76.2 million in 2024, then jumped by 1056.85% to $881.4 million in 2025, then plunged by 108.46% to -$74.6 million in 2026.
• Business Quant data shows LKFT's EBITDA at -$74.6 million in Q1 2026, $881.4 million in Q4 2025, and -$538.5 million in Q3 2025.